EVMN Evommune, Inc.
Evommune, Inc. (EVMN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $452.6K.
Where they traded
Last open-market purchase: July 8, 2026 , by Carver Kyle .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Carver Kyle | Chief Financial Officer | Buy | 1,000 | $13.26 | $13.3K | 60,335 | |
| KIRSCH ARTHUR S | Director | Buy | 10,000 | $13.30 | $133.0K | 10,000 | |
| Drew Janice Suzann | Chief of Dev. Operations | Sell 10b5-1 | 20,000 | $22.63 | $452.6K | 67,794 −22.8% of holding | |
| Pena Luis C. | President & CEO | Sell 10b5-1 | 7,438 | $22.71 | $168.9K | 630,458 −1.2% of holding | |
| Patel Jeegar Pravinkumar | Chief Scientific Officer | Sell 10b5-1 | 1,488 | $22.50 | $33.5K | 46,403 −3.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.